Alliqua, Inc. (NASDAQ:ALQA) (“Alliqua” or “the Company”) has appointed
Janice M. Smiell, M.D. as its Chief Medical Officer, a newly created
position.
Dr. Smiell has more than two decades of experience in clinical trial
design, clinical development and planning, and clinical regulatory
submissions. In practice as a general surgeon, she has specialized in
wound healing, wound care and trauma. Most recently, she was an
independent consultant in drug, device, tissue and cells clinical
development planning, as well as medical monitoring and management.
Prior to this, she served as VP, Medical Affairs at LifeCell
Corporation, where she established the clinical operations, biometrics
and safety departments. Earlier, as Executive Director of Clinical R&D
at Celgene Corporation, she initially led the clinical development of
biomaterials and stem cells and subsequently oversaw research teams
developing immune modulators in several indications. She also served in
various positions of increasing responsibility at The R.W. Johnson
Pharmaceutical Research Institute, including Senior Director, Global
Clinical R&D. Prior to this, she served as Medical Director of The Wound
Care Center at Morristown Memorial Hospital. She holds an M.D. degree
from the Medical College of Pennsylvania.
Dr. Smiell said, “As a veteran of the wound healing and wound care
space, I am acutely aware of the need for significant innovation in this
area. I am extremely enthusiastic about Alliqua’s vision of offering a
suite of products that target a broad spectrum of wound conditions. I am
greatly looking forward to working with Alliqua’s management team to
help evaluate new technologies and expand the company’s portfolio to
address diverse wound care needs, as well as to coordinate our clinical
trials.”
David Johnson, Chief Executive Officer of Alliqua, said, “Dr. Janice
Smiell brings a tremendous amount of management and clinical experience
to Alliqua, and we are honored to have her serve as our Chief Medical
Officer. In an era in which the wound care space is evolving faster than
ever, it is imperative that we have top-notch guidance to navigate the
scientific, technical and regulatory milestones ahead of us. I am
confident that Dr. Smiell, as Alliqua’s first Chief Medical Officer, is
the ideal person to assist us in these efforts over the coming years as
we grow our wound care product portfolio.”
About Alliqua, Inc.
Alliqua, Inc. (ALQAD) ("Alliqua") is a biopharmaceutical company focused
on the development, manufacturing, and distribution of proprietary
transdermal wound care and drug delivery technologies. Alliqua's
technology platform produces hydrogels, a 3-dimensional cross-linked
network of water soluble polymers capable of numerous chemical
configurations.
Alliqua currently markets its line of 510(k) FDA-approved hydrogel
products for wound care under the SilverSeal® brand, as well as the
sorbion sachet S and sorbion sana wound care products. Alliqua's
electron beam production process, located at its 16,000 square foot GMP
manufacturing facility in Langhorne, PA, allows Alliqua to develop and
custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can
be customized for various transdermal applications to address market
opportunities in the treatment of wounds as well as the delivery of
numerous drugs or other agents for pharmaceutical and cosmetic
industries. Additionally, Alliqua's drug delivery platform, in
combination with certain active pharmaceutical ingredients, can provide
pharmaceutical companies with a transdermal technology to enhance
patient compliance and potentially extend the patent life of valuable
drug franchises.
For additional information, please visit http://www.alliqua.com.
To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Any statements contained in this press release regarding our ongoing
research and development and the results attained by us to-date have not
been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking
statements are generally identifiable by the use of words like "may,"
"will," "should," "could," "expect," "anticipate," "estimate,"
"believe," "intend," or "project" or the negative of these words or
other variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous factors and uncertainties
outside of our control that can make such statements untrue, including,
but not limited to, inadequate capital, adverse economic conditions,
intense competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, termination of contracts or agreements, technological
obsolescence of our products, technical problems with our research and
products, price increases for supplies and components, inability to
carry out research, development and commercialization plans, loss or
retirement of key executives and research scientists and other specific
risks. We currently have no commercial products intended to diagnose,
treat, prevent or cure any disease. The statements contained in this
press release regarding our ongoing research and development and the
results attained by us to-date have not been evaluated by the Food and
Drug Administration. There can be no assurance that further research and
development, and/or whether clinical trial results, if any, will
validate and support the results of our preliminary research and
studies. Further, there can be no assurance that the necessary
regulatory approvals will be obtained or that we will be able to develop
new products on the basis of our technologies. In addition, other
factors that could cause actual results to differ materially are
discussed in our Annual Report on Form 10-K/A filed with the SEC on May
16, 2013, and our most recent Form 10-Q filings with the SEC. Investors
and security holders are urged to read these documents free of charge on
the SEC's web site at http://www.sec.gov.
We undertake no obligation to publicly update or revise our
forward-looking statements as a result of new information, future events
or otherwise.
Copyright Business Wire 2014